https://www.inpda.org 2026-03-03T11:24:51+00:00 https://www.inpda.org/sanofi-genzyme-begins-pivotal-phase-23-trial-for-asmd/ 2016-08-01T09:16:18+01:00 https://www.inpda.org/update-on-aidnpc-clinical-programme-notes-from-teleconference/ 2016-08-01T09:17:12+01:00 https://www.inpda.org/fda-grants-fast-track-designation-for-arimoclomol-phase-iii-clinical-investigation/ 2016-08-01T09:19:01+01:00 https://www.inpda.org/orphazyme-begins-dosing-of-np-c-patients-in-arimoclomol-aidnpc-interventional-study/ 2016-08-01T09:21:08+01:00 https://www.inpda.org/fda-gives-clearance-to-arimoclomol-study-for-treatment-of-np-c/ 2016-08-01T09:27:52+01:00 https://www.inpda.org/newborn-screening-test-developed-for-np-c/ 2016-08-01T09:30:39+01:00 https://www.inpda.org/aidnpc-summary-of-teleconference-minutes-31st-march-2016/ 2016-08-01T09:33:29+01:00 https://www.inpda.org/summary-of-inpdas-face-to-face-meeting-mainz-october-2015/ 2016-08-01T09:36:23+01:00 https://www.inpda.org/positive-review-of-paediatric-investigation-plan-pip-for-aidnpc/ 2016-08-01T09:37:36+01:00 https://www.inpda.org/inpda-receives-patient-advocacy-leadership-award/ 2016-08-01T09:38:44+01:00 https://www.inpda.org/aidnpc-teleconference-minutes-26th-november/ 2016-08-01T09:42:17+01:00 https://www.inpda.org/aidnpc-clinical-programme-change-earlier-initiation-of-interventional-study/ 2016-08-01T09:43:21+01:00 https://www.inpda.org/imagine-the-np-c-awareness-short-film-is-now-subtitled-in-ten-languages/ 2016-08-01T09:45:17+01:00 http://www.inpda.org/wp-content/uploads/2015/06/Imagine.jpg https://www.inpda.org/launch-of-dedicated-website-to-orphazymes-aidnpc-clinical-programme/ 2016-08-01T09:54:53+01:00 https://www.inpda.org/orphazyme-announces-update-to-its-aidnpc-clinical-programme/ 2016-08-01T09:55:52+01:00 https://www.inpda.org/great-divide-mountain-bike-ride-for-think-again-think-npc/ 2016-08-01T10:01:25+01:00 https://www.inpda.org/wp-content/uploads/2015/09/banff07.jpg https://www.inpda.org/wp-content/uploads/2015/09/Banff9.jpg https://www.inpda.org/think-again-think-npc-at-the-ssiem-annual-symposium-in-lyon-france/ 2016-08-01T10:20:51+01:00 https://www.inpda.org/wp-content/uploads/2015/09/TATN-at-SSIEM-2015.png https://www.inpda.org/imagine-awareness-film-now-available-with-subtitles/ 2016-08-01T10:25:48+01:00 https://www.inpda.org/calporta-therapeutics-is-developing-small-molecule-agonists-of-trpml1-for-niemann-pick-c/ 2016-08-01T10:26:18+01:00 https://www.inpda.org/genzyme-trial-for-np-b-first-paediatric-patient-dosed-with-investigational-ert/ 2016-08-01T10:30:51+01:00 https://www.inpda.org/imagine-short-film-released/ 2016-08-01T10:32:45+01:00 https://www.inpda.org/imagine-short-film-to-be-premiered-this-weekend-13th-july/ 2016-08-01T10:35:46+01:00 http://www.inpda.org/wp-content/uploads/2015/06/Imagine.jpg https://www.inpda.org/fda-grants-breakthrough-therapy-designation-for-genzymes-olipudase-alfa/ 2016-08-01T10:36:49+01:00 https://www.inpda.org/orphazymes-prospective-non-therapeutic-study-in-patients-diagnosed-with-niemann-pick-disease-type-c/ 2016-08-01T10:40:03+01:00 https://www.inpda.org/test-post-2/ 2016-08-01T10:41:05+01:00 https://www.inpda.org/test-post-3/ 2016-08-01T10:43:24+01:00 https://www.inpda.org/wp-content/uploads/2015/02/BBC-News-article-e1433857104552.png https://www.inpda.org/hello-world/ 2016-08-01T10:44:53+01:00 https://www.inpda.org/orphazyme-update-8-on-the-aidnpc-clinical-programme/ 2016-08-01T12:00:35+01:00 https://www.inpda.org/wp-content/uploads/2016/08/Orphazyme1.jpg https://www.inpda.org/wp-content/uploads/2016/08/AidNPC1.jpg https://www.inpda.org/wp-content/uploads/2016/08/Study-Design.jpg https://www.inpda.org/orphazyme-update-9-on-the-aidnpc-clinical-programme/ 2016-09-05T11:21:05+01:00 https://www.inpda.org/wp-content/uploads/2016/08/Orphazyme1.jpg https://www.inpda.org/wp-content/uploads/2016/08/AidNPC1.jpg http://www.inpda.org/wp-content/uploads/2016/09/Study-Design-CT-ORZY-NPC-002.jpg https://www.inpda.org/ctd-holdings-update-on-trappsol-cyclo/ 2016-09-09T11:47:18+01:00 https://www.inpda.org/orphazyme-heat-shock-protein/ 2016-09-09T15:07:43+01:00 https://www.inpda.org/wp-content/uploads/2016/08/Orphazyme1.jpg http://www.inpda.org/wp-content/uploads/2016/09/Heat-Shock-Protein.jpg https://www.inpda.org/orphazyme-update-10-on-the-aidnpc-clinical-programme/ 2016-09-26T13:05:44+01:00 https://www.inpda.org/wp-content/uploads/2016/08/Orphazyme1.jpg https://www.inpda.org/wp-content/uploads/2016/08/AidNPC1.jpg https://www.inpda.org/wp-content/uploads/2016/09/Study-Design-CT-ORZY-NPC-002.jpg https://www.inpda.org/update-inpda/ 2016-10-26T09:53:29+01:00 https://www.inpda.org/wp-content/uploads/2016/10/INPDR-Logo.png https://www.inpda.org/wp-content/uploads/2016/10/TATN-Logo.jpg https://www.inpda.org/perlara-novartis-niemann-pick-disease/ 2016-10-27T14:06:02+01:00 http://www.inpda.org/wp-content/uploads/2016/10/Perlara-logo-header-1650x621px-9.15.16.jpg https://www.inpda.org/the-quinn-madeline-foundation-establishes-first-ever-niemann-pick-diagnostic-carrier-screening-programme/ 2016-10-28T13:45:07+01:00 https://www.inpda.org/wp-content/uploads/2016/10/Press-Release-Screening-Program.jpg https://www.inpda.org/rani-voncxz/ 2016-10-28T16:31:38+01:00 https://www.inpda.org/wp-content/uploads/2016/10/14641986_771929519576531_7073683558510299389_n.jpg https://www.inpda.org/orphazyme-update-11-aidnpc/ 2016-10-31T09:14:52+00:00 http://www.inpda.org/wp-content/uploads/2016/10/Orphazyme1.jpg http://www.inpda.org/wp-content/uploads/2016/10/AidNPC1.jpg http://www.inpda.org/wp-content/uploads/2016/10/Study-Design-CT-ORZY-NPC-002.jpg https://www.inpda.org/clinical-update-orphazyme-expands-npc-study-to-three-sites-in-the-usa/ 2016-11-03T15:00:28+00:00 http://www.inpda.org/wp-content/uploads/2016/10/Orphazyme1.jpg https://www.inpda.org/jim-green-cnpda-visit/ 2016-11-03T15:17:10+00:00 http://www.inpda.org/wp-content/uploads/2016/11/inpda-logo.jpg https://www.inpda.org/sanofi-genzyme-pivotal-phase/ 2016-11-07T15:02:40+00:00 https://www.inpda.org/wp-content/uploads/2017/07/Agenda-NPD-Scientific-Symposium-Beijing-07Sep2017_v11-1.pdf https://www.inpda.org/ctd-holdings-files-clinical-trial-application-with-italian-drug-agency-to-continue-advancing-trappsolr-cyclotm-drug-development-program-to-treat-niemann-pick-disease-type-c/ 2016-12-22T10:55:44+00:00 http://www.inpda.org/wp-content/uploads/2016/12/Marketwired-Logo-RGB-JPG_124346.jpg http://www.inpda.org/wp-content/uploads/2016/12/ctd_holdings_inc.png https://www.inpda.org/orphazyme-update-12-on-the-aidnpc-clinical-programme/ 2017-01-04T11:41:14+00:00 https://www.inpda.org/wp-content/uploads/2016/10/Orphazyme1.jpg https://www.inpda.org/wp-content/uploads/2016/10/AidNPC1.jpg https://www.inpda.org/wp-content/uploads/2017/01/Study-Design1.jpg https://www.inpda.org/the-first-three-year-old-in-the-world-to-receive-enzyme-therapy-for-niemann-pick-type-b/ 2017-01-05T09:11:48+00:00 https://www.inpda.org/wp-content/uploads/2017/01/15909791_10155292492050663_929526604_n.jpg https://www.inpda.org/npb-enzyme-therapy-luiz-henrique/ 2017-01-09T10:35:51+00:00 http://www.inpda.org/wp-content/uploads/2017/01/IMG-20170106-WA0009.jpg https://www.inpda.org/perlara-pbc-announces-patient-advocacy-group-partnerships/ 2017-01-13T15:03:41+00:00 https://www.inpda.org/wp-content/uploads/2017/01/Perlara-logo-header-1650x621px-9.15.16.jpg https://www.inpda.org/wylder-nation-link-with-perlara/ 2017-01-13T17:10:47+00:00 https://www.inpda.org/wp-content/uploads/2017/01/images.jpg https://www.inpda.org/wp-content/uploads/2017/01/20160110lnp1-demo1.jpg https://www.inpda.org/ctd-holdings-receives-fda-fast-track-designation-for-development-of-trappsol-cyclo-to-treat-niemann-pick-disease-type-c/ 2017-01-17T15:16:21+00:00 https://www.inpda.org/wp-content/uploads/2016/12/ctd_holdings_inc.png https://www.inpda.org/orphazyme-update-13-on-the-aidnpc-clinical-programme/ 2017-01-31T14:11:05+00:00 https://www.inpda.org/wp-content/uploads/2016/10/Orphazyme1.jpg https://www.inpda.org/wp-content/uploads/2016/10/AidNPC1.jpg http://www.inpda.org/wp-content/uploads/2017/01/Graph.jpg https://www.inpda.org/ctd-holdings-initiates-recruitment-for-u-s-phase-i-clinical-study-of-trappsol-cyclo-for-treatment-of-niemann-pick-disease-type-c-patients-to-be-enrolled-at-childrens-hospital/ 2017-03-29T09:00:11+01:00 https://www.inpda.org/wp-content/uploads/2016/12/ctd_holdings_inc.png https://www.inpda.org/update-15-on-the-aidnpc-clinical-programme/ 2017-04-03T15:01:23+01:00 https://www.inpda.org/wp-content/uploads/2016/10/Orphazyme1.jpg https://www.inpda.org/wp-content/uploads/2016/10/AidNPC1.jpg https://www.inpda.org/wp-content/uploads/2016/10/Study-Design-CT-ORZY-NPC-002.jpg https://www.inpda.org/orphazyme-completes-its-enrolment-of-patients-for-phase-3-clinical-trial-in-niemann-pick-type-c-disease/ 2017-05-12T10:29:00+01:00 http://www.inpda.org/wp-content/uploads/2016/10/Orphazyme1.jpg https://www.inpda.org/ctd-holdings-host-webinar-provide-update-trappsol-cyclo-drug-development-program-treatment-niemann-pick-disease-type-c/ 2017-05-18T11:38:43+01:00 https://www.inpda.org/wp-content/uploads/2016/12/ctd_holdings_inc.png https://www.inpda.org/orphazyme-update-16-on-the-aidnpc-clinical-programme/ 2017-06-02T14:38:37+01:00 https://www.inpda.org/wp-content/uploads/2016/10/Orphazyme1.jpg https://www.inpda.org/wp-content/uploads/2016/10/AidNPC1.jpg http://www.inpda.org/wp-content/uploads/2016/10/Study-Design-CT-ORZY-NPC-002.jpg https://www.inpda.org/pactimo-online-charity-shop-now-open/ 2017-06-12T08:56:28+01:00 http://www.inpda.org/wp-content/uploads/2017/06/19376730368_ff15f5f99d_o.jpg https://www.inpda.org/ctd-holdings-announces-appointments-of-two-patient-liaisons-to-enhance-outreach-to-niemann-pick-disease-type-c-families-and-caregivers/ 2017-06-16T17:32:35+01:00 https://www.inpda.org/the-annual-vml-members-weekend/ 2017-06-19T13:47:50+01:00 https://www.inpda.org/wp-content/uploads/2017/06/8.png https://www.inpda.org/wp-content/uploads/2017/06/7.jpg https://www.inpda.org/wp-content/uploads/2017/06/6.jpg https://www.inpda.org/wp-content/uploads/2017/06/5.jpg https://www.inpda.org/wp-content/uploads/2017/06/4.jpg https://www.inpda.org/wp-content/uploads/2017/06/3.jpg https://www.inpda.org/wp-content/uploads/2017/06/2.jpg https://www.inpda.org/wp-content/uploads/2017/06/1.jpg https://www.inpda.org/ctd-holdings-enrolls-first-patient-european-phase-iii-clinical-trial-trappsol-cyclo-treatment-niemann-pick-disease-type-c/ 2017-06-22T09:04:22+01:00 https://www.inpda.org/ctd-holdings-ships-additional-trappsol-cyclo-to-brazil/ 2017-06-27T15:15:27+01:00 https://www.inpda.org/sanofi-genzyme-clinical-trial-update-regarding-ascend-trial-adults-asmd/ 2017-07-04T14:58:20+01:00 https://www.inpda.org/wp-content/uploads/2017/07/Logo-Sanofi-Genzyme.jpg https://www.inpda.org/development-gene-therapy-np-c-ucl/ 2017-07-10T11:15:54+01:00 https://www.inpda.org/ara-parseghian-2151923-282017/ 2017-08-03T10:44:16+01:00 http://www.inpda.org/wp-content/uploads/2017/08/20452051_1839876646039153_5121220002343704279_o.jpg https://www.inpda.org/12th-annual-icord-conference-6th-china-rare-disease-summit/ 2017-08-09T13:40:43+01:00 https://www.inpda.org/wp-content/uploads/2017/07/12th-Annual-ICORD.png https://www.inpda.org/ctd-holdings-announces-approval-clinical-trial-application-conduct-phase-iii-clinical-study-trappsolr-cyclotm-patients-niemann-pick-type-c-disease-israel/ 2017-09-20T13:38:13+01:00 https://www.inpda.org/update-17-on-the-aidnpc-clinical-programme/ 2017-10-05T09:43:35+01:00 https://www.inpda.org/wp-content/uploads/2016/08/Orphazyme1.jpg https://www.inpda.org/wp-content/uploads/2016/10/AidNPC1.jpg http://www.inpda.org/wp-content/uploads/2017/10/Map.png https://www.inpda.org/wp-content/uploads/2017/01/Graph.jpg https://www.inpda.org/introducing-inpdr-facebook-page/ 2017-10-09T13:29:02+01:00 https://www.inpda.org/wp-content/uploads/2017/10/Untitled-1.jpg https://www.inpda.org/new-treatment-disease-swells-organs-gives-new-hope-4-year-old-girl/ 2017-10-25T12:52:37+01:00 https://www.inpda.org/wp-content/uploads/2017/10/18out2017-isadora-bender-prateleira-4-faz-um-tratamento-experimental-para-niemann-pick-b-1508344589279_615x300.jpg https://www.inpda.org/wp-content/uploads/2017/10/19out2017-em-janeiro-deste-ano-a-pequena-isadora-foi-selecionada-para-participar-dos-testes-1508444984632_615x300.jpg https://www.inpda.org/wp-content/uploads/2017/10/campanha-para-tratamento-de-niemann-pick-b-1508349667229_615x300.jpg https://www.inpda.org/orphazyme-anders-hinsby-npc-community/ 2017-11-20T09:59:03+00:00 https://www.inpda.org/wp-content/uploads/2016/10/Orphazyme1.jpg https://www.inpda.org/ctd-holdings-receives-rare-pediatric-disease-designation-trappsol-cyclo/ 2017-12-13T12:38:05+00:00 https://www.inpda.org/wp-content/uploads/2016/12/ctd_holdings_inc.png https://www.inpda.org/chin-huei-wu-%e5%b7%ab%e9%8c%a6%e8%bc%9d-npuk-story/ 2018-01-10T15:03:33+00:00 https://www.inpda.org/update-18-orphazyme-aidnpc-clinical-programme/ 2018-01-17T16:30:30+00:00 http://www.inpda.org/wp-content/uploads/2016/10/Orphazyme1.jpg http://www.inpda.org/wp-content/uploads/2016/10/AidNPC1.jpg http://www.inpda.org/wp-content/uploads/2018/01/Graphs.png http://www.inpda.org/wp-content/uploads/2018/01/w.png https://www.inpda.org/ctd-holdings-conducts-initial-review-safety-data-phase-phase-iii-trials-trappsol-cyclo-treat-niemann-pick-disease-type-c/ 2018-04-04T09:18:07+01:00 https://www.inpda.org/ctd-holdings-closes-2-00-million-private-placement/ 2018-04-24T09:32:15+01:00 https://www.inpda.org/fda-authorizes-ctd-proceed-extension-protocol-us-phase-trappsol-cyclo-trial-niemann-pick-disease-type-c/ 2018-05-01T09:56:52+01:00 https://www.inpda.org/the-data-protection-law-is-changing/ 2018-05-09T10:48:15+01:00 https://www.inpda.org/wp-content/uploads/2018/05/GDPR_960x540.jpg https://www.inpda.org/chin-huei-wu-taiwan-niemann-pick-disease-patient-group/ 2018-05-18T09:47:28+01:00 https://www.inpda.org/international-niemann-pick-disease-registry-inpdr/ 2018-08-16T11:16:39+01:00 https://www.inpda.org/orphazyme-reports-encouraging-arimoclomol-clinical-trial-top-line-data-niemann-pick-disease-type-c-np-c/ 2018-10-09T12:16:16+01:00 http://www.inpda.org/wp-content/uploads/2018/10/Orphazyme1-1024x251.jpg https://www.inpda.org/niemann-pick-disease-type-c-np-c-gene-therapy-activation-meeting-gam/ 2018-11-13T08:56:40+00:00 https://www.inpda.org/wp-content/uploads/2018/11/GAM.png https://www.inpda.org/loire-valley-2018-info-pack/ 2018-11-13T09:46:04+00:00 https://www.inpda.org/wp-content/uploads/2018/11/Loire-Valley-1.jpg https://www.inpda.org/wp-content/uploads/2018/11/Loire-Valley-2.jpg https://www.inpda.org/wp-content/uploads/2018/11/Loire-Valley-4.jpg https://www.inpda.org/wp-content/uploads/2018/11/Loire-Valley-5.jpg https://www.inpda.org/wp-content/uploads/2018/11/Loire-Valley-6.jpg https://www.inpda.org/wp-content/uploads/2018/11/Loire-Valley-7.jpg https://www.inpda.org/wp-content/uploads/2018/11/Loire-Valley-8.jpg https://www.inpda.org/wp-content/uploads/2018/11/Loire-Valley-9.jpg https://www.inpda.org/wp-content/uploads/2018/11/Loire-Valley-10.jpg https://www.inpda.org/wp-content/uploads/2018/11/Loire-Valley-11.jpg https://www.inpda.org/wp-content/uploads/2018/11/Loire-Valley-12.jpg https://www.inpda.org/wp-content/uploads/2018/11/Loire-Valley-13.jpg https://www.inpda.org/wp-content/uploads/2018/11/Loire-Valley-14.jpg https://www.inpda.org/wp-content/uploads/2018/11/Loire-Valley-15.jpg https://www.inpda.org/wp-content/uploads/2018/11/Loire-Valley-16.jpg https://www.inpda.org/wp-content/uploads/2018/11/Loire-Valley-17.jpg https://www.inpda.org/orphazyme-expects-announce-results-full-data-set-niemann-pick-disease-type-c-npc-phase-iiiii-trial-q1-2019/ 2018-12-11T11:51:54+00:00 http://www.inpda.org/wp-content/uploads/2018/10/Orphazyme1-1024x251.jpg https://www.inpda.org/sanofi-genzyme-ascend-ascend-peds-studies-complete-enrollment/ 2019-01-08T14:49:00+00:00 https://www.inpda.org/wp-content/uploads/2019/01/Sanofi-Genzyme-RGB-Colors-e1487877036783.png https://www.inpda.org/ctd-announces-presentation-upcoming-conference-lysosomal-storage-diseases/ 2019-01-11T09:00:45+00:00 https://www.inpda.org/ctd-announces-partnership-united-biosource-llc-support-extension-protocol-phase-clinical-trial-united-states/ 2019-01-18T15:01:59+00:00 https://www.inpda.org/orphazyme-reports-positive-results-full-data-set-phase-iiiii-arimoclomol-trial-niemann-pick-disease-type-c-npc/ 2019-01-30T08:48:36+00:00 https://www.inpda.org/jjs-story-living-asmd/ 2019-02-28T15:25:20+00:00 https://www.inpda.org/ctd-holdings-announces-grant-u-s-non-profit-organization-support-patient-participation-informational-meetings-regulators/ 2019-03-01T12:58:03+00:00 https://www.inpda.org/intrabio-clinical-trial-authorization-application-approved-mhra-treatment-niemann-pick-disease-type-c-npc/ 2019-03-11T14:00:11+00:00 https://www.inpda.org/ctd-holdings-announces-plan-launch-clinical-trial-trappsol-cyclo-alzheimers-disease/ 2019-03-15T15:08:34+00:00 https://www.inpda.org/raphael-beaugillet-road-para-cycling-world-cup/ 2019-04-30T10:09:33+01:00 http://www.inpda.org/wp-content/uploads/2019/04/Raphael-5.jpg https://www.inpda.org/ctd-announces-new-expanded-access-program-taiwan-using-trappsol-cyclo-niemann-pick-disease-type-c/ 2019-05-08T10:58:58+01:00 https://www.inpda.org/international-niemann-pick-disease-alliance-6th-biennial-face-face-meeting/ 2019-05-08T16:09:35+01:00 https://www.inpda.org/wp-content/uploads/2019/05/inpda-logo.jpg http://www.inpda.org/wp-content/uploads/2015/04/Toronto-2017.jpg http://www.inpda.org/wp-content/uploads/2019/05/nbf.png https://www.inpda.org/wp-content/uploads/2019/05/hfh.png https://www.inpda.org/ctd-announces-participation-support-upcoming-gathering-patient-support-organizations-niemann-pick-disease-type-c/ 2019-05-16T15:07:05+01:00 https://www.inpda.org/ctd-announces-home-based-dosing-first-patient-us-extension-protocol-clinical-trial-using-intravenous-administration-trappsol-cyclo-niemann-pick-disease-type-c/ 2019-05-24T10:00:00+01:00 https://www.inpda.org/ctd-holdings-closes-7-4-million-private-placement/ 2019-06-03T09:03:55+01:00 https://www.inpda.org/orphazyme-prepare-filing-arimoclomol-europe-niemann-pick-disease-type-c-npc/ 2019-06-11T12:11:46+01:00 https://www.inpda.org/ctd-appoints-head-global-regulatory-affairs/ 2019-07-09T09:06:18+01:00 https://www.inpda.org/anders-hinsby-letter-np-c-community/ 2019-07-18T15:55:53+01:00 https://www.inpda.org/wp-content/uploads/2017/05/May-newsletter_DE-2.docx https://www.inpda.org/ctd-announces-new-data-presented-annual-gathering-patients-families-tackling-niemann-pick-disease-type-c/ 2019-08-15T15:46:36+01:00 https://www.inpda.org/orphazyme-announces-interim-report-first-half-2019/ 2019-08-30T12:12:14+01:00 https://www.inpda.org/ctd-holdings-present-2019-annual-conference-npc-patients-families-health-professionals-united-kingdom/ 2019-09-12T08:49:46+01:00 https://www.inpda.org/intrabio-clinical-trial-ib1001-201-us-recruitment/ 2019-09-13T18:21:33+01:00 https://www.inpda.org/ctd-holdings-announces-fda-approval-us-expanded-access-treatment-program-niemann-pick-disease-type-c/ 2019-09-13T18:57:29+01:00 https://www.inpda.org/cyclo-therapeutics-announces-support-firefly-funds-newborn-screening-program/ 2019-10-18T13:30:46+01:00 https://www.inpda.org/cyclo-therapeutics-announces-completion-enrollment-phase-trial-evaluate-trappsol-cyclo-treatment-niemann-pick-disease-type-c/ 2019-10-22T14:45:59+01:00 https://www.inpda.org/cyclo-therapeutics-announces-publication-extensive-set-case-study-reports-date-expanded-access-use-hydroxypropyl-beta-cyclodextrin-niemann-pick-disease-type-c/ 2019-10-31T16:39:32+00:00 https://www.inpda.org/orphazyme-receives-breakthrough-therapy-designation-arimoclomol-niemann-pick-disease-type-c-npc/ 2019-11-19T15:26:04+00:00 https://www.inpda.org/cyclo-therapeutics-inc-present-clinical-trial-data-niemann-pick-type-c-disease-16th-annual-worldsymposium/ 2019-12-19T09:39:08+00:00 https://www.inpda.org/claubia-viegas-bender/ 2019-12-20T11:38:53+00:00 http://www.inpda.org/wp-content/uploads/2019/12/Claubia.jpg https://www.inpda.org/expanded-access-programme-eap-an-update-from-orphazyme/ 2019-12-20T15:50:25+00:00 https://www.inpda.org/wp-content/uploads/2018/10/Orphazyme1-1024x251.jpg https://www.inpda.org/orphazyme-reports-positive-arimoclomol-data-open-label-phase-23-extension-niemann-pick-disease-type-c/ 2020-01-03T11:21:27+00:00 https://www.inpda.org/wp-content/uploads/2018/10/Orphazyme1-1024x251.jpg https://www.inpda.org/orphazyme-announcement-us-early-access-program-npc/ 2020-01-06T15:33:25+00:00 https://www.inpda.org/intrabio-neuroprotection-disease-modification-niemann-pick-c-extension-phase-approved-europe/ 2020-01-17T08:39:07+00:00 https://www.inpda.org/intrabio-completes-npc-clinical-trial-enrollment/ 2020-01-17T16:02:12+00:00 https://www.inpda.org/sanofi-positive-topline-results-demonstrated-olipudase-alfa-first-investigational-therapy-late-stage-development-acid-sphingomyelinase-deficiency/ 2020-01-30T16:29:03+00:00 https://www.inpda.org/cyclo-therapeutics-inc-poster-presentation-clinical-trial-data-niemann-pick-type-c-disease-16th-annual-worldsymposium-now-available/ 2020-02-05T16:11:49+00:00 https://www.inpda.org/last-patient-last-visit-cyclo-therapeutics-phase-trial-niemann-pick-type-c/ 2020-02-12T14:32:18+00:00 https://www.inpda.org/cyclo-therapeutics-announces-completion-enrollment-phase-iii-trial-evaluate-trappsol-cyclo-treatment-niemann-pick-disease-type-c/ 2020-02-20T12:41:36+00:00 https://www.inpda.org/cyclo-therapeutics-announces-positive-feedback-fda-pivotal-trial-design-trappsol-cyclo-niemann-pick-disease-type-c1/ 2020-03-02T14:58:50+00:00 https://www.inpda.org/inherited-metabolic-disease-and-coronavirus-covid-19-advice-for-patients-parents-guardians/ 2020-03-05T16:27:57+00:00 http://www.inpda.org/wp-content/uploads/2020/03/lsd-1.png http://www.inpda.org/wp-content/uploads/2020/03/lsd-2.png https://www.inpda.org/cyclo-therapeutics-inc-announces-positive-safety-profile-drug-trappsol-cyclo-treatment-niemann-pick-disease-type-c/ 2020-03-25T10:49:08+00:00 https://www.inpda.org/intrabio-receives-fda-fast-track-designation-niemann-pick-disease/ 2020-03-25T15:57:20+00:00 https://www.inpda.org/message-orphazyme-global-community-patients-family-members-healthcare-providers-impacted-corona-virus-pandemic-covid-19/ 2020-03-27T16:54:01+00:00 https://www.inpda.org/wp-content/uploads/2018/10/Orphazyme1-1024x251.jpg https://www.inpda.org/cyclo-therapeutics-closes-2-0-million-private-placement/ 2020-04-27T13:50:54+01:00 https://www.inpda.org/cyclo-therapeutics-announces-positive-feedback-european-medicines-agency-pivotal-trial-design-trappsol-cyclo-niemann-pick-disease-type-c1/ 2020-05-18T17:53:25+01:00 https://www.inpda.org/cyclo-therapeutics-hold-call-patients-investors-wednesday-may-20-430-pm-edt/ 2020-05-19T15:48:39+01:00 https://www.inpda.org/cyclo-therapeutics-inc-announces-positive-top-line-results-phase-trial-interim-analysis-phase-iii-trial-using-trappsol-cyclo-intravenously-treat-patients-niemann/ 2020-05-21T09:21:16+01:00 https://www.inpda.org/cyclo-therapeutics-clinical-data-webinar-recording-available-company-website/ 2020-05-29T13:40:54+01:00 https://www.inpda.org/orphazyme-completes-rolling-submission-new-drug-application-u-s-fda-arimoclomol-niemann-pick-disease-type-c/ 2020-07-20T15:16:41+01:00 https://www.inpda.org/cyclo-therapeutics-closes-2-8-million-private-placement-led-novit-lp-1-0-million/ 2020-08-28T08:13:06+01:00 https://www.inpda.org/cyclo-therapeutics-inc-announces-additional-efficacy-data-ongoing-phase-iii-trial-using-trappsol-cyclotm-intravenously-treat-patients-niemann-pick-disease-type-c1-npc1/ 2020-09-08T14:23:41+01:00 https://www.inpda.org/orphazyme-announces-u-s-fda-acceptance-priority-review-new-drug-application-arimoclomol-niemann-pick-disease-type-c/ 2020-09-17T11:12:36+01:00 https://www.inpda.org/intrabio-reports-positive-data-ib1001-multinational-clinical-trial-treatment-niemann-pick-disease-type-c/ 2020-09-30T13:23:01+01:00 https://www.inpda.org/intrabio-reports-detail-positive-data-ib1001-multinational-clinical-trial-treatment-niemann-pick-disease-type-c/ 2020-10-19T13:12:37+01:00 https://www.inpda.org/cyclo-therapeutics-phase-3-pivotal-program-can-begin-enrollment-per-us-fda/ 2020-10-22T08:54:46+01:00 https://www.inpda.org/orphazyme-submits-european-marketing-authorisation-application-arimocolmol-treatment-niemann-pick-disease-type-c/ 2020-11-09T08:26:39+00:00 https://www.inpda.org/cyclo-therapeutics-announces-two-presentations-worldsymposium2021/ 2020-11-19T15:23:10+00:00 https://www.inpda.org/inpdr-strategic-business-plan-progress/ 2020-12-01T10:44:18+00:00 https://www.inpda.org/cyclo-therapeutics-announces-pricing-12-5-million-public-offering/ 2020-12-10T09:28:26+00:00 https://www.inpda.org/orphazyme-statement-npc-community/ 2020-12-14T11:38:56+00:00 https://www.inpda.org/sandy-cowie-inpda-president-christmas-message-2020/ 2020-12-22T19:58:37+00:00 https://www.inpda.org/wp-content/uploads/2020/12/inpda-sandy.png https://www.inpda.org/orphazyme-provides-regulatory-update-arimoclomol-npc/ 2020-12-28T12:17:10+00:00 https://www.inpda.org/cyclo-therapeutics-announces-positive-efficacy-data-extension-protocol-trappsol-cyclo-patients-niemann-pick-disease-type-c/ 2021-01-06T08:40:05+00:00 https://www.inpda.org/inpda-spotlight-niemann-pick-selbsthilfegruppe-deutschland-e-v/ 2021-01-21T10:31:12+00:00 https://www.inpda.org/wp-content/uploads/2021/01/INPDA-Member-spotlight.png https://www.inpda.org/wp-content/uploads/2021/01/Deutschland-e.V..jpg https://www.inpda.org/master-protocol-investigate-novel-therapy-acetyl-l-leucine-three-ultra-rare-neurodegenerative-diseases-niemann-pick-type-c-gm2-gangliosidoses-ataxia-telangiectasia/ 2021-01-25T15:04:31+00:00 https://www.inpda.org/cyclo-therapeutics-present-clinical-drug-development-program-lead-candidate-trappsol-cyclo-worldsymposium-2021/ 2021-01-26T15:41:15+00:00 https://www.inpda.org/orphazyme-showcase-data-arimoclomol-niemann-pick-disease-type-c-2021-annual-worldsymposium/ 2021-02-05T17:12:06+00:00 https://www.inpda.org/cyclo-therapeutics-presents-positive-data-clinical-development-program-lead-candidate-trappsol-cyclo-worldsymposium-2021/ 2021-02-09T14:23:51+00:00 https://www.inpda.org/17-de-febrero-dia-nacional-de-niemann-pick-fundacion-niemann-pick-de-espana/ 2021-02-17T09:29:33+00:00 https://www.inpda.org/cyclo-therapeutics-unveils-new-corporate-identity-reaffirms-commitment-improving-quality-life-providing-hope-patients-families/ 2021-02-22T14:33:42+00:00 https://www.inpda.org/orphazyme-appoints-christophe-bourdon-chief-executive-officer/ 2021-03-01T11:30:24+00:00 https://www.inpda.org/cyclo-therapeutics-appoints-gerald-f-cox-md-phd-acting-chief-medical-officer/ 2021-03-01T15:10:21+00:00 https://www.inpda.org/cyclo-therapeutics-announces-last-patient-last-visit-phase-12-trial-evaluating-trappsol-cyclo-treatment-niemann-pick-disease-type-c/ 2021-03-04T15:22:19+00:00 https://www.inpda.org/inpda-spotlight-npsuisse/ 2021-03-08T17:20:43+00:00 https://www.inpda.org/wp-content/uploads/2021/01/INPDA-Member-spotlight.png https://www.inpda.org/wp-content/uploads/2021/03/SUISSE.jpg https://www.inpda.org/cyclo-therapeutics-receives-positive-opinion-paediatric-committee-european-medicines-agency-agreement-paediatric-investigation-plan-trappsol-cyclo/ 2021-03-09T15:15:03+00:00 https://www.inpda.org/cyclo-therapeutics-appoints-russ-belden-acting-chief-commercial-officer/ 2021-03-10T15:28:07+00:00 https://www.inpda.org/cyclo-therapeutics-participate-inaugural-emerging-growth-virtual-conference/ 2021-03-12T13:55:05+00:00 https://www.inpda.org/university-college-london-begins-preclinical-studies-develop-treatment-niemann-pick-c-disease-support-columbus-foundation/ 2021-03-16T12:07:01+00:00 https://www.inpda.org/cyclo-therapeutics-meets-primary-efficacy-endpoint-phase-12-trial-intravenous-trappsol-cyclo-rare-disease-niemann-pick-type-c1-npc1/ 2021-03-25T13:45:19+00:00 https://www.inpda.org/inpda-spotlight-vml-france-niemann-pick-group/ 2021-04-06T09:53:59+01:00 https://www.inpda.org/wp-content/uploads/2021/01/INPDA-Member-spotlight.png https://www.inpda.org/wp-content/uploads/2021/04/VML.jpg https://www.inpda.org/cyclo-therapeutics-inc-update-13421/ 2021-04-14T15:13:20+01:00 https://www.inpda.org/cyclo-therapeutics-announces-design-pivotal-phase-3-study-evaluating-trappsol-cyclo-niemann-pick-type-c1/ 2021-04-27T14:45:17+01:00 https://www.inpda.org/cyclo-therapeutics-appoints-lori-mckenna-gorski-global-head-patient-advocacy/ 2021-05-11T15:25:12+01:00 https://www.inpda.org/orphazyme-npc-community-notification/ 2021-06-18T09:57:13+01:00 https://www.inpda.org/orphazyme-provides-regulatory-update-fda-arimoclomol-niemann-pick-disease-type-c/ 2021-06-18T10:08:13+01:00 https://www.inpda.org/inpda-spotlight-fundacion-niemann-pick-de-espana-fnp/ 2021-06-23T08:50:24+01:00 https://www.inpda.org/wp-content/uploads/2021/01/INPDA-Member-spotlight.png https://www.inpda.org/wp-content/uploads/2021/05/fnp.jpg https://www.inpda.org/inpda-community-webinar-series-cyclo-therapeutics-phase-3-trial/ 2021-06-30T08:50:04+01:00 https://www.inpda.org/orphazyme-presents-36-month-data-supporting-durable-response-arimoclomol-parseghian-scientific-conference-npc-research/ 2021-07-02T15:45:30+01:00 https://www.inpda.org/inpda-spotlight-associazione-italiana-niemann-pick-onlus/ 2021-07-05T10:32:00+01:00 https://www.inpda.org/wp-content/uploads/2021/01/INPDA-Member-spotlight.png https://www.inpda.org/npc-letter-to-fda-13th-august-2021/ 2021-08-19T13:04:06+01:00 https://www.inpda.org/intrabio-reports-statistically-significant-clinically-meaningful-improvements-use-ib1001-treatment-gm2-gangliosidosis-tay-sachs-sandhoff-disease/ 2021-08-19T15:53:35+01:00 https://www.inpda.org/orphazyme-announces-publication-results-phase-23-trial-arimoclomol-niemann-pick-disease-type-c-journal-inherited-metabolic-disease/ 2021-08-24T11:08:49+01:00 https://www.inpda.org/cyclo-therapeutics-appoints-lise-lund-kjems-md-phd-chief-medical-officer/ 2021-09-28T08:46:42+01:00 https://www.inpda.org/orphazyme-provides-regulatory-financial-updates/ 2021-10-05T15:15:28+01:00 https://www.inpda.org/npc-listening-session-aug-3-report/ 2021-10-13T12:58:51+01:00 https://www.inpda.org/orphazyme-provides-regulatory-update-following-type-meeting-fda-arimoclomol-niemann-pick-disease-type-c/ 2021-11-01T14:47:56+00:00 https://www.inpda.org/21st-niemann-pick-sielbstilfegruppe-family-support-meeting-overview/ 2021-11-30T10:11:36+00:00 http://www.inpda.org/wp-content/uploads/2017/06/305019_360971923980719_421567696_n.jpg https://www.inpda.org/ema-accepts-regulatory-submission-olipudase-alfa-first-potential-therapy-asmd/ 2021-12-07T14:28:49+00:00 https://www.inpda.org/cyclo-therapeutics-receives-ind-clearance-u-s-fda-advance-phase-2-study-trappsol-cyclo-treatment-alzheimers-disease/ 2021-12-07T16:34:40+00:00 https://www.inpda.org/changes-executive-management-orphazyme-anders-vadsholt-appointed-ceo/ 2022-02-01T15:55:48+00:00 https://www.inpda.org/cyclo-therapeutics-announces-formation-global-steering-committee-comprised-leading-experts-advise-global-phase-3-clinical-development-program-trappsol-cyclo-niema/ 2022-02-03T16:41:50+00:00 https://www.inpda.org/orphazyme-provides-update-planned-nda-resubmission-arimoclomol-treatment-niemann-pick-disease-type-c-united-states/ 2022-02-11T16:35:32+00:00 https://www.inpda.org/ib1001-301-effects-n-acetyl-l-leucine-niemann-pick-disease-type-c-npc-phase-iii-randomized-placebo-controlled-double-blind-crossover-study/ 2022-02-14T16:34:46+00:00 https://www.inpda.org/orphazyme-announces-update-regulatory-review-arimoclomol-european-union/ 2022-02-24T10:36:40+00:00 https://www.inpda.org/the-global-community-supports-inpdas-letter-to-ema/ 2022-03-17T08:51:30+00:00 https://www.inpda.org/orphazyme-announces-withdrawal-european-marketing-authorisation-application-arimoclomol-treatment-niemann-pick-disease-type-c/ 2022-03-22T19:00:58+00:00 https://www.inpda.org/azafaros-announces-fda-grant-orphan-drug-designation-az-3102-treatment-niemann-pick-disease/ 2022-03-24T14:46:34+00:00 https://www.inpda.org/orphazyme-update-march-2022/ 2022-03-24T18:16:57+00:00 https://www.inpda.org/xenpozyme-olipudase-alfa-approved-japan-first-approved-therapy-indicated-treat-acid-sphingomyelinase-deficiency/ 2022-03-28T18:01:31+01:00 https://www.inpda.org/webinar-the-impacts-of-olipudase-alfa-on-pediatric-patients-with-asmd-and-their-families/ 2022-05-16T09:00:08+01:00 https://www.inpda.org/wp-content/uploads/2022/05/INPDA-email-banner.png https://www.inpda.org/orphazyme-court-restructuring-sell-substantially-assets-business-activities-kempharm-inc/ 2022-05-17T13:22:25+01:00 https://www.inpda.org/transportnpc-scott-fine-ceo-cyclo-therapeutics/ 2022-05-24T09:03:37+01:00 https://www.inpda.org/chmp-recommends-approval-xenpozyme-olipudase-alfa-first-treatment-asmd/ 2022-05-24T09:40:35+01:00 https://www.inpda.org/mandos-npc1-community-newsletter-may-2022/ 2022-05-30T11:42:34+01:00 https://www.inpda.org/intrabio-ib1001-301-international-recruitment/ 2022-06-16T08:37:58+01:00 https://www.inpda.org/press-release-xenpozyme-olipudase-alfa-approved-european-commission-first-treatment-asmd/ 2022-06-28T13:49:21+01:00 https://www.inpda.org/nnpdf-goes-virtual-nnpdf-family-support-medical-conference-2022/ 2022-07-21T12:09:05+01:00 https://www.inpda.org/wp-content/uploads/2022/07/nnpdf.png https://www.inpda.org/xenpozyme-olipudase-alfa-approved-fda-first-disease-specific-treatment-asmd-non-cns-manifestations/ 2022-09-01T09:56:05+01:00 https://www.inpda.org/cyclo-therapeutics-announces-publication-phase-1-data-trappsol-cyclo-treatment-niemann-pick-disease-type-c1-npc1/ 2022-10-19T11:43:21+01:00 https://www.inpda.org/ib1001-301-recruitment-complete/ 2022-12-06T09:51:43+00:00 https://www.inpda.org/azafaros-receives-fdas-ind-clearance-fast-track-designation-lead-asset-az-3102/ 2023-01-10T09:05:18+00:00 https://www.inpda.org/cyclo-therapeutics-phase-3-study-npc-now-enrolling-uk/ 2023-04-20T10:43:48+01:00 https://www.inpda.org/open-letter-npc-community-bloomsbury-genetic-therapies-limited/ 2023-05-19T17:36:21+01:00 https://www.inpda.org/cyclo-therapeutics-phase-3-study-evaluate/ 2023-06-13T12:06:41+01:00 https://www.inpda.org/intrabio-announces-positive-pivotal-trial-results-ib1001-treatment-niemann-pick-disease-type-c/ 2023-06-29T13:00:44+01:00 https://www.inpda.org/cyclo-therapeutics-announces-publication-positive-data-phase-2-clinical-study-trappsol-cyclo-treatment-niemann-pick-disease-type-c1/ 2023-06-30T10:26:26+01:00 https://www.inpda.org/community-statement-kisbee-therapeutics-30th-august-2023/ 2023-08-31T12:16:01+01:00 https://www.inpda.org/shining-spotlight-superstar-siblings-unsung-heroes-npd-awareness-month/ 2023-09-11T12:33:07+01:00 https://www.inpda.org/wp-content/uploads/2023/09/Screenshot-2023-09-11-104255.png https://www.inpda.org/advancing-rare-disease-research-zevras-acquisition-acer-therapeutics/ 2023-09-13T09:15:46+01:00 https://www.inpda.org/cyclo-therapeutics-inc-applied-molecular-transport-inc-enter-definitive-merger-agreement/ 2023-09-22T14:24:06+01:00 https://www.inpda.org/sibling-spotlight-guillermo/ 2023-09-30T10:40:25+01:00 https://www.inpda.org/wp-content/uploads/2023/09/Spanish-1.png https://www.inpda.org/sibling-spotlight-iker/ 2023-09-30T10:43:12+01:00 https://www.inpda.org/wp-content/uploads/2023/09/Spanish-2.png https://www.inpda.org/sibling-spotlight-sara/ 2023-09-30T10:48:25+01:00 https://www.inpda.org/wp-content/uploads/2023/09/Spanish-3.png https://www.inpda.org/sibling-spotlight-alejandro/ 2023-10-05T11:24:59+01:00 https://www.inpda.org/wp-content/uploads/2023/10/img1.png https://www.inpda.org/wp-content/uploads/2023/10/24676-7-horizontal-line-transparent-background-1-2.png https://www.inpda.org/wp-content/uploads/2023/10/img4.png https://www.inpda.org/introducing-neil-f-mcfarlane-zevra-therapeutics-new-president-ceo/ 2023-10-11T09:33:00+01:00 https://www.inpda.org/zevra-acer-deal-close-inpda-npc-pag-letter_/ 2023-11-21T13:07:59+00:00 https://www.inpda.org/introducing-inpda-international-niemann-pick-disease-alliance-executive-committee/ 2023-11-30T15:31:56+00:00 https://www.inpda.org/wp-content/uploads/2023/11/inpda-exec.jpg https://www.inpda.org/cyclo-therapeutics-announces-positive-outcome-from-type-c-meeting-with-the-u-s-fda-discussing-trappsol-cyclo-clinical-program-for-the-treatment-of-niemann-pick-disease-type-c1/ 2023-12-19T08:55:57+00:00 https://www.inpda.org/azafaros-phase-2-rainbow-study-evaluating-nizubaglustat-gm2-npc-patients-now-fully-enrolled/ 2023-12-21T14:08:27+00:00 https://www.inpda.org/nejm-publishes-ib1001-301-trial-results/ 2024-02-02T10:02:09+00:00 https://www.inpda.org/intrabio-nejm-publishes-expert-perspective-editoral-ib1001/ 2024-02-07T15:19:41+00:00 https://www.inpda.org/zevra-therapeutics-fda-extends-review-period-arimoclomol-nda/ 2024-03-06T10:48:25+00:00 https://www.inpda.org/azafaros-completion-12-week/ 2024-03-22T12:55:31+00:00 https://www.inpda.org/azafaros-announces-positive-topline-phase-2-study-data-nizubaglustat/ 2024-07-17T10:17:16+01:00 https://www.inpda.org/gemdac-zevra/ 2024-08-05T10:25:00+01:00 https://www.inpda.org/wp-content/uploads/2024/08/Zevra-Therapeutics-Logo.png https://www.inpda.org/intrabio-announces-u-s-fda-approval-of-aqneursa-for-the-treatment-of-niemann-pick-disease-type-c/ 2024-09-25T13:47:07+01:00 https://www.inpda.org/zevra-npc-community-letter-miplyffa-now-available-usa/ 2024-11-22T10:01:46+00:00 https://www.inpda.org/azafaros-regulatory-designations-europe/ 2025-01-09T11:32:36+00:00 https://www.inpda.org/update-pronto-phase-2-rainbow/ 2025-01-10T12:36:12+00:00 https://www.inpda.org/intrabio-appoints-dr-marc/ 2025-01-14T13:31:42+00:00 https://www.inpda.org/global-access-challenges-niemann-pick-therapies-insights-inpda-community-survey/ 2025-02-24T09:19:27+00:00 https://www.inpda.org/pfriegers-digest-012020-edition/ 2025-07-24T16:32:13+01:00 https://www.inpda.org/pfriegers-digest-022020-edition/ 2025-07-24T16:32:45+01:00 https://www.inpda.org/pfriegers-digest-032020-edition/ 2025-07-24T16:33:08+01:00 https://www.inpda.org/pfriegers-digest-032021-edition/ 2025-07-24T16:33:30+01:00 https://www.inpda.org/pfriegers-digest-092021-edition/ 2025-07-24T16:33:52+01:00 https://www.inpda.org/pfriegers-digest-062022-edition/ 2025-07-24T16:34:08+01:00 https://www.inpda.org/pfriegers-digest-092022-edition/ 2025-07-24T16:34:28+01:00 https://www.inpda.org/pfriegers-digest-032023-edition/ 2025-07-24T16:34:51+01:00 https://www.inpda.org/pfriegers-digest-092023-edition/ 2025-07-24T16:35:10+01:00 https://www.inpda.org/pfriegers-digest-022024-edition/ 2025-07-24T16:35:28+01:00 https://www.inpda.org/pfriegers-digest-13th-issue/ 2025-07-24T16:36:29+01:00 https://www.inpda.org/pfriegers-digest-12th-issue/ 2025-07-24T16:43:02+01:00 https://www.inpda.org/pfriegers-digest-11thissue/ 2025-07-24T16:43:35+01:00 https://www.inpda.org/pfriegers-digest-13th-issue-2/ 2025-07-24T16:43:59+01:00 https://www.inpda.org/zevra-arimoclomol-maa-npc/ 2025-07-29T09:52:23+01:00 https://www.inpda.org/aqneursa-levacetylleucine-recommended-eu-approval-chmp-treat-niemann-pick-disease-type-c/ 2025-07-29T16:51:00+01:00 https://www.inpda.org/azafaros-announces-initiation-two-global-phase-3-studies-nizubaglustat-niemann-pick-disease-type-c-npc-gm1gm2-gangliosidoses-respectively/ 2025-08-18T15:04:00+01:00 https://www.inpda.org/global-inpda-initiatives/ 2026-01-19T13:16:33+00:00 https://www.inpda.org/patient-information-sheet-navigate-phase-3-clinical-trial/ 2026-01-19T16:28:47+00:00 https://www.inpda.org/intrabio-receives-european-commission-approval-aqneursa-treatment-niemann-pick-type-c-disease/ 2026-01-21T13:33:52+00:00 https://www.inpda.org/beren-therapeutics-announcement-npc/ 2026-02-24T13:30:51+00:00 https://www.inpda.org/azafaros-announces-publication-preclinical-efficacy-data-nizubaglustat-gm2-gangliosidosis/ 2026-02-25T10:58:05+00:00 https://www.inpda.org/niemannpick-india/ 2026-03-03T09:40:40+00:00 https://www.inpda.org/beren-therapeutics-adrabetadex-nda-accepted-fda-infantile-onset-niemann-pick-type-c/ 2026-03-03T11:24:51+00:00